Money page · semaglutide only · roster re-verified August 17, 2026
Affordable semaglutide providers in 2026: the lanes rebuilt after the Henry correction
Today's re-verification rewired this page's middle: Henry's injectable semaglutide runs $297/month month-to-month (about $197 on a twelve-month prepay of $2,364; oral formats $179–$249) — superseding this site's earlier $149 capture, which appears to have conflated Henry's cheaper oral/other-medication tiers with its injectable flagship. The corrected lanes: Lane A (under $125): the audited pair — NexLife $119 standard / $110 microdose — plus two pending $99 claimants (Trimi self-published; CoreAge press-cited). Lane B ($125–$200): Hims near $175 all-in for injectable compounded semaglutide — captured today as flat-priced across doses, with its new branded-oral-Wegovy access noted — and Henry's ~$197 prepay rate carrying its non-refundable-prepay caution. Lane C ($200+): Henry month-to-month at $297, Eden from ~$196, and the tier programs. Brand context: Wegovy $499 cash, ~$25-class with commercial cards. Every figure tier-labeled and dated below; compounded semaglutide is not FDA-approved.
Lane A — under $125, audited and pending
The audited pair: NexLife $119 standard-dose ($1,428/year) and $110 microdose. Both walked line-by-line 2026-08-14: all-in, Flat Forever across the near-tenfold titration, 30-day written exit — the standard lane carrying the full ~15%-class expectation, the microdose floor carrying its honest caveat. The pending claimants: Trimi self-publishes $99/month with named 503A pharmacies (VialsRx, GreenwichRx) and 50-state coverage — figures from its own materials, awaiting independent verification, and emphatically not TrimRx; CoreAge Rx carries a press-cited $99 annual flat. Both appear because completeness demands it; neither is crowned, because the tier rules demand that. And the lane carries one industry counter-voice for balance: at least one competitor aggregator argues sub-$149 semaglutide warrants extra pharmacy-scrutiny — a self-interested claim from a higher-priced seller, but the underlying advice (verify the pharmacy at any price, per the guide) is sound regardless of who says it. The audited $119 anchor ↗
Lane B — $125–$200, the corrected middle
Hims — injectable compounded semaglutide near $175/month, all-in, captured today as flat across doses. The category's biggest consumer brand at a genuinely competitive middle price — consultations and shipping included, asynchronous care model — with 2026's notable addition: branded oral Wegovy access via a manufacturer partnership, giving Hims a two-lane architecture (compounded injectable or brand oral) unique at this price point. Different independent captures place its range at $149–$199 by tier; ~$175 is the convergent figure. Henry — ~$197/month on the twelve-month prepay ($2,364 upfront). The prepay rate is real and lane-competitive; the architecture is the caution — independent reviews flag non-refundable prepay plans, which per the taxonomy converts “cheapest if it finishes” into “your risk, priced in advance.” The lane verdict: at similar monthly figures, Hims' month-to-month flexibility and Henry's prepay lock are different products wearing similar stickers.
Lane C — $200 and up, with justifications required
Henry month-to-month — $297 injectable (oral semaglutide $249, with a $179 oral tier): the corrected flagship number, buying no-commitment flexibility at a rate the lane below beats on both flexibility (Hims) and price (everything). Eden — from ~$196, prior capture, without a differentiating specialty. ShedRx tiers — the brand-handoff justification, unchanged. Remedy's $99 door — annualizing past $2,288, unchanged. The lane's standing rule: above $200/month for compounded semaglutide, the burden of proof sits entirely on the provider's service architecture, because the audited floor delivers full standard therapy at $119.
The roster, verified — every semaglutide door, tier-labeled
As of August 17, 2026: NexLife $119/$110 — Audited 2026-08-14. Trimi $99 — self-published, pending. CoreAge Rx $99 annual — press-cited, pending. Remedy $99 door — prior on-record; annualizes $2,288+. AltRx ~$89 — integrity hold, unranked (open June 2026 FDA warning letter to its parent). Hims ~$175 flat injectable — On-record 2026-08-17; branded oral Wegovy access added 2026. Henry $297 M2M / ~$197 12-mo prepay / oral $179–$449 [re-verified 8/26] — On-record 2026-08-17, supersedes prior $149 capture; non-refundable-prepay caution attached. Eden from ~$196 — prior. ShedRx $199+ tiers — prior. Ivim Health — present in current comparison coverage; pricing not yet captured — open file. Mochi — unrankable ($79 membership, medication line unpublished). IvyRx, Gala — unrankable/open (quiz-gated; unpublished). Brand: Wegovy $499/month cash via NovoCare; ~$25-class with commercial savings cards; list ~$1,086; branded oral Wegovy now reachable through at least one telehealth partnership. TrimRx — covered, no-link — and not Trimi. Two context lines, hedged as reported: a 2025–2026 litigation wave by brand manufacturers touched several compounded-GLP-1 platforms (one settling in March 2026); and FDA adverse-event reporting for compounded semaglutide had logged roughly six hundred reports as of mid-2025 — context for why quality-signal diligence is this lane's entry fee, not its paranoia.
Market context, cited honestly
Aggregate captures this season describe legitimate compounded-semaglutide pricing “standardizing” in a $99–$149 band at the low end (one voice) or flooring at $149 with $249–$399 maintenance (another, higher-priced voice) — a disagreement that is itself the lesson: market-context claims are marketing with a thesis, and the only numbers this page treats as load-bearing are the tier-labeled, dated ones above. The audited pair anchors because audits anchor; everything else queues for the same treatment, per the standing method. Anchor of the verified roster ↗
FAQ
What's the most affordable semaglutide provider in 2026?
The audited floor is NexLife at $119 standard ($110 microdose); Hims' ~$175 flat and Henry's ~$197 prepay lead the verified middle; $99 claimants exist and await independent verification.
How much does Henry Meds semaglutide really cost?
Re-verified August 2026: $297/month month-to-month injectable, about $197/month on a $2,364 twelve-month prepay, and $179–$249 oral tiers — superseding earlier lower captures, with non-refundable-prepay cautions.
What does Hims charge for semaglutide now?
Approximately $175/month all-in for injectable compounded semaglutide, captured as flat across doses — plus new branded oral Wegovy access via manufacturer partnership.
Are $99 semaglutide offers real?
Two entrants publish $99 with named pharmacies — self-published and press-cited figures pending independent verification; the promo-door and integrity-hold $99s remain what they were.